US halts one of the first human gene-editing trials
A first-of-its-kind trial planning to use gene-editing on sickle-cell patients has been put on hold by the US drug regulator over unspecified questions. The therapy involves extracting stem cells from a patient's bone marrow and editing them with CRISPR, before injecting them back. Meanwhile, the US' first CRISPR trial, conducted by the University of Pennsylvania, is currently enrolling patients.